Attacking stress tolerance in cancer

攻击癌症的压力耐受性

基本信息

  • 批准号:
    10685400
  • 负责人:
  • 金额:
    $ 88.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-18 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract My career began with the identification of cell surface markers on invasive cells, and led to the discovery of how integrins αvβ3 and αvβ5 on endothelial cells respond to cues within the tumor microenvironment to promote angiogenesis. I later demonstrated that αV integrins on tumor cells use these same fundamental pathways to achieve aggressive, invasive, and metastatic behavior. Now, my R35 proposal represents a further evolution of these concepts to ask how tumor cells undergo reprogramming in response to cellular stresses, including hypoxia, nutrient deprivation, or cancer therapy. We find that αvβ3 expression can be induced by stress to reprogram tumor cells toward a stress-tolerant, drug-resistant, stem-like state that is associated with tumor progression and metastasis for a wide range of cancers. Because individual tumors use this integrin to overcome unique challenges, we will define how αvβ3 activates downstream effectors that vary between tumor type, genetic profile, and microenvironment. The overall goal of my future research program is to understand how such tumors use integrin αvβ3 to gain stress tolerance so that we can devise ways to attack this process therapeutically. This proposed research will not only lead to a fundamental understanding of how tumors adapt to therapy or microenvironmental stress, but it should identify new druggable targets to limit cancer progression by preventing or overcoming tumor cell drug resistance and stress tolerance.
项目总结/文摘

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Metastasis is a highly stressful process.
  • DOI:
    10.1007/s10555-020-09938-y
  • 发表时间:
    2020-12
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Campos AD;Weis SM;Cheresh DA
  • 通讯作者:
    Cheresh DA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A CHERESH其他文献

DAVID A CHERESH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A CHERESH', 18)}}的其他基金

Attacking stress tolerance in cancer
攻击癌症的压力耐受性
  • 批准号:
    10411424
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Exploiting KRAS addiction for lung cancer therapy
利用 KRAS 成瘾进行肺癌治疗
  • 批准号:
    10474614
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Attacking stress tolerance in cancer
攻击癌症的压力耐受性
  • 批准号:
    10062746
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Attacking stress tolerance in cancer
攻击癌症的压力耐受性
  • 批准号:
    10237176
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Attacking stress tolerance in cancer
攻击癌症的压力耐受性
  • 批准号:
    10474361
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Exploiting KRAS addiction for lung cancer therapy
利用 KRAS 成瘾进行肺癌治疗
  • 批准号:
    9788292
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Attacking stress tolerance in cancer
攻击癌症的压力耐受性
  • 批准号:
    10182631
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Attacking stress tolerance in cancer
攻击癌症的压力耐受性
  • 批准号:
    10524197
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Exploiting KRAS addiction for lung cancer therapy
利用 KRAS 成瘾进行肺癌治疗
  • 批准号:
    10246401
  • 财政年份:
    2018
  • 资助金额:
    $ 88.3万
  • 项目类别:
Targeting a non-canonical RAS-driven pathway in pancreatic cancer
靶向胰腺癌中非经典 RAS 驱动的通路
  • 批准号:
    8495296
  • 财政年份:
    2012
  • 资助金额:
    $ 88.3万
  • 项目类别:

相似海外基金

Basic Cancer Research in Cancer Health Disparities
癌症健康差异的基础癌症研究
  • 批准号:
    8725605
  • 财政年份:
    2012
  • 资助金额:
    $ 88.3万
  • 项目类别:
Basic Cancer Research in Cancer Health Disparities
癌症健康差异的基础癌症研究
  • 批准号:
    9136772
  • 财政年份:
    2012
  • 资助金额:
    $ 88.3万
  • 项目类别:
Basic Cancer Research in Cancer Health Disparities
癌症健康差异的基础癌症研究
  • 批准号:
    8389026
  • 财政年份:
    2012
  • 资助金额:
    $ 88.3万
  • 项目类别:
Basic Cancer Research in Cancer Health Disparities
癌症健康差异的基础癌症研究
  • 批准号:
    8547797
  • 财政年份:
    2012
  • 资助金额:
    $ 88.3万
  • 项目类别:
10th Annual McGill Biomedical Conference: Advances in Basic Cancer Research
第十届麦吉尔生物医学年会:基础癌症研究进展
  • 批准号:
    193204
  • 财政年份:
    2009
  • 资助金额:
    $ 88.3万
  • 项目类别:
    Miscellaneous Programs
Consolidated Basic Cancer Research Program
综合基础癌症研究计划
  • 批准号:
    8625567
  • 财政年份:
    1997
  • 资助金额:
    $ 88.3万
  • 项目类别:
Consolidated Basic Cancer Research Program
综合基础癌症研究计划
  • 批准号:
    8894146
  • 财政年份:
    1997
  • 资助金额:
    $ 88.3万
  • 项目类别:
Consolidated Basic Cancer Research Program
综合基础癌症研究计划
  • 批准号:
    8666280
  • 财政年份:
    1997
  • 资助金额:
    $ 88.3万
  • 项目类别:
Consolidated Basic Cancer Research Program
综合基础癌症研究计划
  • 批准号:
    10244063
  • 财政年份:
    1997
  • 资助金额:
    $ 88.3万
  • 项目类别:
Consolidated Basic Cancer Research Program
综合基础癌症研究计划
  • 批准号:
    10570928
  • 财政年份:
    1997
  • 资助金额:
    $ 88.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了